Neumora Therapeutics, Inc. Common Stock beat EPS estimates 50% of the time across 4 reported quarters (2 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.23 | $-0.23 | +0.0% | Beat |
| Q22026 FY2026 | $-0.23 | $-0.33 | -43.5% | Miss |
| Q12026 FY2026 | $-0.32 | $-0.30 | +6.3% | Beat |
| Q42025 FY2025 | $-0.34 | $-0.35 | -2.9% | Miss |
| Q12026 FY2026 | $-0.34 | — | — | Miss |
Back to NMRA overview · NMRA holders · NMRA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.